Pharmaceuticals

Chronic CME After ARN

Persistent CME may be caused by inflammatory and ischemic mechanisms, even after apparent viral quiescence.

Collin Richards, MD, and David Fell, MD

What Pathogen Type Reveals About Endophthalmitis

Certain types of bacteria may be linked to a more aggressive disease course post-procedure.

Saagar Patel, MD; Christopher Conrady, MD, PhD; and Talisa E. De Carlo Forest, MD

The Potential of Tyrosine Kinase Inhibitors

This novel class of drug may one day help to address the growing burden of diabetic eye disease.

Shawn Kavoussi, MD

Be Wary of Macular Hole After Anti-VEGF Injection

This complication, although rare, is still possible.

Carlos Mario Rangel, MD; Karol Quintero Lizcano, MD; Maria Isabel Corrales, MD; Maria A. Piedrahita, MD; and Virgilio Galvis, MD

A Look at Orphan Drug Development in Retina

The regulatory pathway has matured, and the commercial and reimbursement lessons have sharpened.

Thomas A. Ciulla, MD, MBA

Beyond One-Size-Fits-All: The Move Toward Personalized Vitreoretinal Therapy

By calculating the vitreous volume exact, clinicians can treat eyes with greater precision.

Andreas F. Borkenstein, MD

Drug Interactions in Immunosuppressive Therapy for Uveitis

A review of the toxic relationships to avoid when managing patients with uveitis.

Ioannis Papasavvas, MD, and Carl P. Herbort, Jr, MD, PD

Vigabatrin-Related Retinal Toxicity

Patients taking this medication for epilepsy should be monitored carefully for visual disturbances.

Natalia Londoño De Vivero, MD; Rafael Méndez Marulanda, MD; Daniela Rojas Pérez, MD; Clemencia De Vivero Arciniegas, MD; and Álvaro Mejía Vergara, MD

Using PPAR Agonists to Treat DR

This class of drugs warrants further investigation of its potential to mitigate microvascular damage and improve patient outcomes.

Tahir Ishrak Khan, MPharma, and Divya Balram Jha, MPharma

Treating Uveitis Today and Tomorrow

Many novel therapies are under investigation to treat noninfectious uveitis and uveitic macular edema.

Yesde Esther Son, MD, PhD, and Tedi Begaj, MD

The Pipeline: TL;DR

Allen C. Ho, MD, and Robert L. Avery, MD

Nutritional Supplementation for IRDs: Preservation or Placebo?

Recent evidence suggests some benefits, but more work is needed.

Paula Morales, MD; Cesar Estrada-Puente, MD; and Ramiro Maldonado, MD

Implantable Drug Delivery: A Look At Pharmacokinetics

Novel approaches are showing promise for addressing treatment burden in retinal disease.

Charles C. Wykoff, MD, PhD, FASRS, FACS

Acute Retinopathy Following Weightlifting Supplement

An unusual case demonstrates the value of inquiring about a patient’s lifestyle and nutrition in relation to their visual symptoms.

Sayena Jabbehdari, MD, MPH, MBA; Abdelrahman M. Elhusseiny, MD, MSc; William A. Henry, MD; and Velimir Petrovic, MD

An Update on Sustained Drug Delivery in Retina

Unique ways to address treatment burden for patients with retinal conditions.

Deepak Sambhara, MD, and Marin Stowe, BS

Managing Wet AMD: The Promise of TKIs

This novel approach may help to mitigate the treatment burden associated with wet AMD therapy.

Rahul Iyengar, MD; Douglas Matsunaga, MD; and David S. Boyer, MD

Tailoring IVT Dosing With Vitreous Volume

We have heard the adage, “As much as necessary, as little as possible,” with regard to medication. Can we apply it to intravitreal therapy?

Andreas F. Borkenstein, MD

Retinal Capillary Hemangioblastomas in VHL

Case studies suggest a novel therapeutic may be able to treat these vision-threatening ocular tumors.

Corrina P. Azarcon, MD, DPBO; Imaan Zera Kherani, MD; and Amin Kherani, MD, FRCSC, FASRS

Managing The Ocular Effects of Steroid Overdose

Improper use to boost athletic performance caused this case of retinal vascular occlusion.

Fernando Godin, MD; Nimesh A. Patel, MD; Eduardo Cadena, MD; Diana Concha, MD; Maria Adelaida Piedrahita, MD; and Carolina Parra, MD

PVR Pipeline Roundup

At ASRS 2023, experts discussed two medical therapies under investigation.

Alex Brodin